Research Guide
How regulatory events change company value
IND clearance, Phase II data, pivotal trial design, NDA/BLA submission, advisory committees, and approval decisions each change the evidence package in different ways. Good analysis asks what uncertainty has been reduced, and what risk remains.
What to check first
Start with the evidence that can change value: clinical relevance, regulatory path, competitive context, financing needs, and whether the company can reach the next milestone.
How Drugnews uses this guide
We apply these frameworks when writing company research, paid analysis, and client-facing content so that readers can follow the logic behind each judgment.